highlighted the transformative role of personalized medicine in gastrointestinal (GI) cancer treatment through advances in next-generation sequencing and circulating tumor DNA, while emphasizing ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

In fact, the earlier you get treatment, the easier the cancer ... doctor to figure out if they could be caused by a GI disorder, colorectal cancer, or another problem. Trust your instincts ...

A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...

Alarmed by the color and frequency of the blood in her stool, Mahon was referred to a GI doctor who initially thought she had an autoimmune disease. “Once I got the colonoscopy, she told me that she ...

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

While colon cancer has traditionally been associated with older adults, recent data reveals an alarming trend: cases are ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new ...

Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for ...

New data from two studies presented at ASCO GI 2025 demonstrated that ctDNA testing could predict recurrence risk in ...